Velcade "Impressive" Efficacy Offsets Concern Over Response As Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Millennium’s multiple myeloma agent response rate is "better than expected," NDA review documents indicate. FDA reverses its initial request for Phase III study results to support accelerated approval after final data from Phase II are submitted.
You may also be interested in...
Millennium Velcade Supplement Seeks Full Approval, Second-Line Use
The company hopes to convert Velcade's accelerated approval for third-line use to full approval and add a second-line multiple myeloma indication based on the Phase III APEX trial, which showed a significant survival benefit.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).